- Categories
- Satellite Symposium
Evolving Standards of Care: Bispecific Antibodies in NHL
-
,
Shanghai 1-2
Endorsed by: AbbVie
-
SAFE IMPLEMENTATION: ASTCT-graded CRS/ICANS: monitoring and infection risk management.
- Presentation time:
- 10 min
-
EVIDENCE → PRACTICE: Clinical evidence: Phase 2/3 trial data for bispecific antibodies in NHL, Treatment positioning and sequencing
- Presentation time:
- 20 min
-
FOUNDATION, CD20×CD3 mechanism and off-the-shelf use vs CAR-T
- Presentation time:
- 10 min